Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Christian Ehmann - Warburg Research Benjamin Jackson - Jefferies Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Nine Months 2024 Capital Market Briefing Conference Call. I am Sachin, the Chorus Call Operator.

Evotec SE (EVO) Q3 2024 Earnings Call Transcript

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec's "Priority Reset" initiative launched in April 2024, which aims to foster profitable growth by refining the company's operational footprint and focusing on its primary growth sectors and core competencies.

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process.

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec.

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Novo Nordisk

On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Evotec and Novo Nordisk forge technology development partnership

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.

Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec's Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first in Europe, utilizes Just - Evotec Biologics' adaptable J.POD® technology to provide essential clinical and commercial biologics manufacturing capacity.

Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

SAN DIEGO--(BUSINESS WIRE)-- #Evotec--Life science leader Evotec partners with Scientist.com to streamline access to its cutting-edge drug discovery and development solutions.

Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development

WALTHAM, Mass.--(BUSINESS WIRE)--Evotec SE and X-Chem announces a collaboration agreement focused on accelerating early-stage drug discovery. .

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions HAMBURG, GERMANY / ACCESSWIRE / September 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024.

Evotec Announces Change in Management Board

Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition.

Evotec: Weak Performance, But Long-Term Potential Is There

Evotec SE (NASDAQ:EVO ) Q2 2024 Earnings Conference Call August 14, 2024 8:00 AM ET Company Participants Volker Braun - Executive Vice President, Head of Global Investor Relations and ESG Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Matthias Evers - Chief Business Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Benjamin Jackson - Jefferies Michael Ryskin - Bank of America Steven Mah - TD Cowen Falko Friedrichs - Deutsche Bank Stephan Wulf - ODDO BHF Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2024 Conference Call. I am Udith, the Chorus Call Operator.

Evotec SE (EVO) Q2 2024 Earnings Call Transcript

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated Challenging market environment and high fixed cost base led to weaker profitability.

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE / August 13, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progress of the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based achievements trigger payments of in total US$ 75 m to Evotec.

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE Reports First Half-year 2024 Results on 14 August 2024

Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales order book in Discovery is basis for a moderate growth acceleration in H2 2024; conversion of orders into revenues taking longer than anticipated Reset towards sustainable profitable growth starts getting traction and will be enhanced to make Evotec more agile in a still challenging market environment HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has refined its guidance for the fiscal year 2024. For the current fiscal year, the Company expects Revenues1 in the range of € 790 - 820 m (low to mid-single-digit percentage growth vs previously low double-digit percentage growth; 2023: € 781.4 m); R&D expenditures are expected in a range of € 50 - 60 m (low double-digit percentage reduction vs previously mid-single to low double-digit percentage reduction; 2023: € 64.8 m); Adjusted EBITDA1 is expected to reach € 15 - 35 m (mid-double-digit percentage reduction vs previously mid double-digit percentage growth; 2023: € 66.4 m).

Evotec Provides Guidance Update

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the range of € 790 - 820 m (low to mid-single-digit percentage growth vs previously low double-digit percentage growth; 2023: € 781.4 m); R&D expenditures are expected in a range of € 50 - 60 m (low double-digit percentage reduction vs previously mid-single to low double-digit percentage reduction; 2023: € 64.8 m); Adjusted EBITDA is expected to reach € 15 - 35 m (mid double-digit percentage reduction vs previously mid double-digit percentage growth; 2023: € 66.4 m).

Evotec SE Provides Guidance Update

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / July 8, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced that its biologics segment, Just - Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz. Just - Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025.

Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz

Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program Manufacturing Optimization Program effort enhances U.S. Government's rapid response capabilities for biologics MCMs in response to emergency situations HAMBURGSUND, SWEDEN / ACCESSWIRE / June 25, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., was selected by the U.S. Department of Defense ("DOD") to develop an accelerated monoclonal antibody ("mAb") development and manufacturing solution for the DOD's Manufacturing Optimization Program. The multi-year program award, valued up to $ 39 m, will support the U.S. Government's effort to enhance its rapid response capabilities for biologics medical countermeasures ("MCMs").

Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program

Bristol-Myers

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

News for Evotec SE Stock (EVO)